Whether its basic research or late-stage tech development, our institute is built to provide the tools and expertise you need. The platform management department is affiliated with IBMC and provides professional analysis and testing, experiments and consulting services to research institutes, affiliated hospitals and research institutions. At present, the department has more than 100 kinds of scientific research equipment, including more than 60 large-scale scientific research instruments. In the future, it will develop into a large-scale integrated open platform integrating technology development, scientific research support, clinical services and industrial cooperation.
The platform is equipped with large instruments such as a high-content imaging system, ultra-resolution SIM microscope, dual photon confocal microscope, turntable confocal microscope, single-molecule TIRF imaging system, and so forth. We strive to provide comprehensive micro-imaging and image analysis services. Our facilities are also equipped with flow sorting, multi-color flow analysis, nano-flow and other equipment to provide cell and molecular biology-related technical services.
The platform is equipped with a high-resolution liquid phase mass spectrometry instrument, MALDI-TOF, ICP mass spectrometer, gas phase mass spectrometer, high-efficiency liquid chromatography, circular dichromatometer, Fourier infrared spectrometer, ultraviolet visible spectrophotometry meter, full function steady-state and transient fluorescence spectrometers, as well as other world-class experimental equipment. We provide mass spectrometry imaging, comprehensive characterization of polymers, material identification and structural analysis, and elemental analysis for pharmacy, biochemistry, clinical applications, and histological research.
The platform is equipped with a transmission electronmicroscope, scanning electron microscope, atomic force microscope, magnetic tweezer force spectrum test system, nuclear magnetic resonance spectrometer,and other world-class experimental equipment. The platform can provide 2D/3D high-resolution imaging of materials and samples, micromorphology and composition information of samples, qualitative/quantitative analysis of crystal structure, tribology of samples, and electrical and magnetic analysis of samples.
The center carries out molecular diagnosis and automated detection of major diseases such as malignant tumors and major infectious diseases. The center focuses on developing precision detection technology for tumors and pathogenic microorganisms, instant intelligent detection equipment and home-type, project-based joint inspection products, building artificial intelligence and blockchain-assisted diagnosis and treatment and health management platform driven by medical big data, and improving the early warning and detection capabilities of major diseases.
The center is committed to establishing high-throughput and low-cost next-generation screening technologies that can quickly generate aptamers for different targets such as small molecules, proteins, cells, body fluids, and even organs for specific needs. The center focuses on breaking through the technical bottleneck of aptamers and providing innovative research tools and a technology platform for the research of oncology and basic medicine.
Developing novel medicine is a cornerstone of IBMC. We work on addressing the technical barriers of cell therapy and develop small molecule drug candidates. We also have laboratories devoted to gastric cancer intelligent surgery and to studying proteomics.
The center was officially established in 2019 under the leadership of the University-affiliated Oncology Hospital of the Chinese Academy of Sciences. The center efficiently integrates internal medicine, surgery, radiation, and chemotherapy through collaborations with the Cancer Foundation Institute, MD Anderson Cancer Institute and domestic institutes.
The center works towards achieving safe and autonomous control, thereby reducing ECMO treatment costs, increasing performance and saving more lives. The lead unit and enterprise are responsible for the research and development and registered production of ECMO medical devices, and the hospital is responsible for the clinical verification and development of ECMO medical devices.